Open AccessReview: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
Author(s) -
Oriana Simonetti,
Giulio Rizzetto,
Elisa Molinelli,
Oscar Cirioni,
Annamaria Offidani
Publication year - 2021
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s271445
Subject(s) - dalbavancin , medicine , adverse effect , incidence (geometry) , safety profile , randomized controlled trial , clinical trial , pharmacology , vancomycin , physics , biology , bacteria , optics , genetics , staphylococcus aureus
Dalbavancin is a bactericidal lipoglycopeptide active against gram-positives. Its use has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI).